Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.
Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check9 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference1.0%
- Check16 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.9%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.1%
- Check52 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2.SummaryDifference0.1%
- Check73 days agoChange DetectedThe study has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.4%
Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.